Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328650 | 0.82 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL2909221 | 0.79 | HPRT1 (0.34) | HSP90AA1HSP90AB1CCNE1CDK2CDK1 | |
| SCHEMBL13328618 | 0.76 | HSP90AB1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL12999109 | 0.76 | HSP90AB1 (0.38) | HSP90AA1HSP90AB1CCNE1CDK2CDK1 | |
| SCHEMBL14629615 | 0.76 | CYP3A4 (0.41) | HSP90AA1HSP90AB1CCNE1CDK2CDK1 | |
| SCHEMBL2906275 | 0.75 | POLB (0.38) | CCNE1CDK2CDK1CCNB1POLB | |
| SCHEMBL13328633 | 0.74 | HSP90AB1 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL13360613 | 0.74 | HPRT1 (0.36) | HSP90AA1HSP90AB1CCNE1CDK2HPRT1 | |
| SCHEMBL13714842 | 0.71 | CCNE1 (0.44) | HSP90AA1HSP90AB1CCNE1CDK2CDK1 | |
| SCHEMBL2914746 | 0.71 | FAP (0.49) | POLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2010-01-07 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | HSP90AA1 4081/4885HSP90AB1 3304/4885CCNE1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.